To read the full story, subscribe or sign in.

GW Pharma preps for 4 phase III Epidiolex trials in childhood epilepsy

March 10, 2015

LONDON – GW Pharma plc is poised to launch four U.S. phase III trials of its second cannabis-derived drug Epidiolex, in the treatment of childhood epilepsy.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....